Journal of neurology, neurosurgery, and psychiatry
-
J. Neurol. Neurosurg. Psychiatr. · Jul 2023
Genetically determined serum serine level has a novel causal effect on multiple sclerosis risk and predicts disability progression.
There are currently no specific biomarkers for multiple sclerosis (MS). Identifying robust biomarkers for MS is crucial to improve disease diagnosis and management. ⋯ These findings support investigating serine as an important candidate biomarker for MS onset and disability progression.
-
J. Neurol. Neurosurg. Psychiatr. · Jul 2023
Multicenter StudySpinal cord reserve in multiple sclerosis.
The spinal cord (SC) is a preferential target of multiple sclerosis (MS) damage highly relevant towards disability. Differential impact of such damage could be due to the initial amount of SC tissue, as described for the brain parenchyma (brain reserve concept). We aimed to test the existence of SC reserve by using spinal canal area (SCaA) as a proxy. ⋯ A larger SCaA may be protective against disability in MS, possibly supporting the existence of SC reserve.
-
J. Neurol. Neurosurg. Psychiatr. · Jul 2023
Long-term outcomes of moyamoya disease versus atherosclerosis-associated moyamoya vasculopathy using high-resolution MR vessel wall imaging.
We aimed to compare the long-term outcomes and surgical benefits between moyamoya disease (MMD) and atherosclerosis-associated moyamoya vasculopathy (AS-MMV) using high-resolution MRI (HRMRI). ⋯ Patients with MMD had a higher risk of ischaemic stroke than those with AS-MMV, and patients with both MMD and AS-MMV could benefit from EDAS. Our findings suggest that HRMRI could be used to identify those who are at a higher risk of future cerebrovascular events.
-
J. Neurol. Neurosurg. Psychiatr. · Jul 2023
Multiple sclerosis mortality in New Zealand: a nationwide prospective study.
Mortality data from Europe and North America show a shorter life expectancy for people with multiple sclerosis (MS). It is not known if a similar mortality risk exists in the southern hemisphere. We analysed the mortality outcomes of a comprehensive New Zealand (NZ) MS cohort, 15 years postrecruitment. ⋯ New Zealanders with MS have a median survival age 7.2 years lower than the general population and twice the mortality risk. The survival gap was greater for progressive-onset disease and for those with an early age of onset.